Giovanni Scambia

Researcher Next ID · RN-002565

Researcher · Medicine

Milan, Italy

Not currently recruitingFunding unknown

Research interests

Medicine

Ovarian cancer diagnosis and treatment

Endometrial and Cervical Cancer Treatments

PARP inhibition in cancer therapy

Uterine Myomas and Treatments

Intraperitoneal and Appendiceal Malignancies

Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
New England Journal of Medicine · 2019 · https://doi.org/10.1056/nejmoa1911361
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
New England Journal of Medicine · 2018 · https://doi.org/10.1056/nejmoa1810858
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
The Lancet Oncology · 2017 · https://doi.org/10.1016/s1470-2045(17)30469-2
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
The Lancet · 2017 · https://doi.org/10.1016/s0140-6736(17)32440-6
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
The Lancet · 2017 · https://doi.org/10.1016/s0140-6736(17)32440-6

No projects listed.